Keeping Track: Xiidra, New Repatha Regimen Approved; Abuse-Deterrent Opioid Gets Negative, But Timely, Response

 
• By Bridget Silverman

The latest drug development news and highlights from our FDA Performance Tracker.

More from Approvals

More from Product Reviews